A Case of JC Virus Granule Cell Neuronopathy in an HIV+ Patient Presenting with Severe Ataxia

Jennifer Adrisi, MD1, Mashina Chomba, MBChB3, Lorraine Chishimba, MBChB3, Stanley Zimba, MBChB, MMED3, Hrav Attarian, MD1, Igor Koralnik, MD1, Deanna Saylor, MD MHS2,3

Background

- JC Virus Granule Cell Neuronopathy (JCV GCN) is a lytic infection of granule cells in the cerebellum caused by reactivation of JC Virus (JCV) in immunocompromised hosts.1
- JCV is a polyomavirus that is also the causative agent for progressive multifocal leukoencephalopathy (PML), a demyelinating disorder also on the differential for abnormal brain lesions in the immunocompromised. Unlike PML, JCV GCN is contained to the cerebellum and spares the white matter.1,2

Case Report

A 42-year-old male with a past medical history of HIV on highly active antiretroviral therapy (HAART) presented with one year of progressive neurologic decline. He presented with progressive gait instability, incoordination, slurred speech, and difficulty swallowing. By the time of hospital presentation, he was unable to walk, and his speech was unintelligible due to severe dysarthria. His exam was notable for severe ocular and appendicular dysmetria, truncal ataxia, and dysarthria.

Laboratory analysis was most notable for a CD4 count of 218 cells/mm³, and cerebrospinal fluid (CSF) analysis was unremarkable. JCV testing was not available.

Brain CT was notable for significant bilateral cerebellar atrophy with relative preservation of the white matter and cerebral hemispheres leading to the diagnosis of possible JCV GCN based on clinical presentation and imaging findings.

Discussion

In an immunocompromised patient presenting with clinical and radiologic signs of cerebellar degeneration, there should be a low threshold to consider JCV GCN. The disease has been reported in multiple immunosuppressed populations including patients with HIV, multiple sclerosis on natalizumab, and lymphoma on immunotherapy.3,4 In HIV populations, adequate viral suppression and HAART adherence is important in helping to prevent worsening neurologic symptoms in this condition. Increased HIV screening and faster implementation of HAART therapy may help to prevent JCV GCN.

There are 1.2 million people living with HIV in Zambia including 10% of adults aged 15 - 59 in its capital, Lusaka.6,7 JCV GCN can be the first manifestation of AIDS in this population. Lack of access to specialized healthcare, labs, and imaging in resource-limited settings may lead to under-diagnosis of JCV GCN. With both PML and JCV GCN on the differential for the patient discussed, it was important to advocate for imaging to further the diagnostic workup.

Results

- While unable to obtain a JCV PCR, we made a clinical diagnosis of possible JCV GCN based on clinical presentation and imaging.
- The patient was diagnosed with virologic failure of his HAART therapy (CD4 count 35) 7 months prior to this admission requiring a switch to second line HAART. While unclear, it was hypothesized that the patient may have had increased susceptibility to JCV reactivation and subsequent JCV GCN during this unknown duration of inadequate viral suppression.
- He received physical therapy during his admission and was discharged home with family with plan for continued outpatient follow-up in infectious disease clinic for HIV management.

References

JC Virus Granule Cell Neuronopathy (JCV GCN) is a lytic infection of granule cells in the cerebellum caused by reactivation of JC Virus (JCV) in immunocompromised hosts.\textsuperscript{1}

JCV is a polyomavirus that is also the causative agent for progressive multifocal leukoencephalopathy (PML), a demyelinating disorder also on the differential for abnormal brain lesions in the immunocompromised. Unlike PML, JCV GCN is contained to the cerebellum and spares the white matter.\textsuperscript{1,2}
Case Presentation

- A 42-year-old male with a past medical history of HIV on highly active antiretroviral therapy (HAART) presented with one year of progressive neurologic decline.

- He presented with progressive gait instability, incoordination, slurred speech, and difficulty swallowing. By the time of hospital presentation, he was unable to walk, and his speech was unintelligible due to severe dysarthria.

- His exam was notable for severe ocular and appendicular dysmetria, truncal ataxia, and dysarthria.

- Laboratory analysis was most notable for a CD4 count of 218 cells/mm³, and cerebrospinal fluid (CSF) analysis was unremarkable. JCV testing was not available.
Brain CT was notable for significant bilateral cerebellar atrophy with relative preservation of the white matter and cerebral hemispheres.
Results

• While unable to obtain a JCV PCR, we made a clinical diagnosis of possible JCV GCN based on clinical presentation and imaging.

• The patient was diagnosed with virologic failure of his HAART therapy (CD4 count 35) 7 months prior to this admission requiring a switch to second line HAART. While unclear, it was hypothesized that the patient may have had increased susceptibility to JCV reactivation and subsequent JCV GCN during this unknown duration of inadequate viral suppression.
In an immunocompromised patient presenting with clinical and radiologic signs of cerebellar degeneration, there should be a low threshold to consider JCV GCN.

The disease has been reported in multiple immunosuppressed populations including patients with HIV, multiple sclerosis on natalizumab, and lymphoma on immunotherapy.3,4,5
In HIV populations, adequate viral suppression and HAART adherence is important in helping to prevent worsening neurologic symptoms in this condition.

There are 1.2 million people living with HIV in Zambia including 16% of adults aged 15 - 59 in its capital, Lusaka. JCV GCN can be the first manifestation of AIDS in this population. Lack of access to specialized healthcare, labs, and imaging in resource-limited settings may lead to under-diagnosis of JCV GCN.
# References


